ホーム › 転移性癌 › カリフォルニア州 › Irvine
Irvine、CAにおける転移性癌の臨床試験
Irvineとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
被験者募集中第1相
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- City of Hope at Irvine Lennar, Irvine
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
被験者募集中第1相
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UCI Health - Irvine, Irvine
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- City of Hope Lennar, Irvine
- Kaiser Permanente Zion Medical Center, Irvine
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
被験者募集中第1相
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
被験者募集中第1/2相
- City of Hope at Irvine Lennar, Irvine
- City of Hope Investigational Drug Services (IDS), Irvine
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
被験者募集中第2相
- City of Hope at Irvine Lennar, Irvine
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
被験者募集中第1/2相
- City of Hope - Orange County Lennar Foundation Cancer Center, Irvine
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Hoag Hospital Center, Irvine
- Hoag Hospital Irvine, Irvine
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
被験者募集中第1/2相
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
被験者募集中第1相
- City of Hope - Lennar, Irvine
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Irvine
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
被験者募集中第1相
- UC Irvine, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
被験者募集中第1/2相
- University of California, Irvine, Irvine
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Irvineにおける他の研究
- 非小細胞肺癌25件の研究
- 乳がん23件の研究
- がん（全種類）17件の研究
- 肺がん15件の研究
- 多発性骨髄腫14件の研究
- 前立腺がん14件の研究
- 卵巣がん12件の研究
- 頭頸部扁平上皮癌11件の研究
- 膀胱癌11件の研究
- アルツハイマー病11件の研究
- 大腸癌10件の研究
- 膵臓がん10件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。